Retatrutide

Retatrutide is an investigational triple-receptor agonist peptide being developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. This mechanism delivered notable weight-loss results in clinical trials: 24.2% body-weight reduction at 48 weeks in the peer-reviewed Phase 2 trial (Jastreboff et al., NEJM 2023), with preliminary Phase 3 topline data reporting further gains. It is being studied for advanced metabolic support in obesity and type 2 diabetes. Typical trial dosing ranges from 1 mg to 12 mg once weekly via subcutaneous injection, with gradual escalation over ~12 weeks.Specification: 10 mg per vial · 99%+ purity · lyophilized powder · for laboratory and research use only. Not for human or veterinary use.

• Supplied as a lyophilized powder for laboratory reconstitution.
• HPLC purity and mass-spec identity verified on every lot.
• Backed by a lot-specific Certificate of Analysis.
• Strictly for in-vitro research use only.

Reconstitute with bacteriostatic or sterile water as appropriate for your protocol. Store reconstituted material refrigerated and use within the timeframe indicated by your research procedures.